Compare FICO & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FICO | BBIO |
|---|---|---|
| Founded | 1956 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3B | 13.3B |
| IPO Year | 1995 | 2019 |
| Metric | FICO | BBIO |
|---|---|---|
| Price | $671.96 | $78.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 22 |
| Target Price | ★ $821.37 | $107.00 |
| AVG Volume (30 Days) | 700.9K | ★ 2.7M |
| Earning Date | 11-04-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 36.85 | N/A |
| EPS | ★ 36.32 | N/A |
| Revenue | ★ $1,032,475,000.00 | $502,076,000.00 |
| Revenue This Year | $2.20 | $118.56 |
| Revenue Next Year | $6.47 | $51.71 |
| P/E Ratio | $18.62 | ★ N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $595.19 | $62.50 |
| 52 Week High | $1,858.91 | $93.42 |
| Indicator | FICO | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 38.04 | 60.89 |
| Support Level | $662.30 | $63.62 |
| Resistance Level | $760.65 | $85.42 |
| Average True Range (ATR) | 33.72 | 2.96 |
| MACD | 1.41 | 0.13 |
| Stochastic Oscillator | 25.17 | 60.59 |
Founded in 1956, Fair Isaac is a leading applied analytics company. It is primarily known for its FICO credit scores, a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's US-centric credit scores business accounts for most of the firm's revenue and profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. Its key drug is Attruby (acoramidis), an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.